Global and China China Charging/Swapping Research Report 2024: For Vehicle-to-Grid (V2G), OEMs Set Foot in the Electricity Sales Side Reform and Virtual Power Plants, and Explore Business Models
September 26, 2024 07:26 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "China Charging/Swapping (Liquid Cooling Overcharging System, Small Power, Swapping, V2G, etc) Research Report, 2024" report has been added to ...
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences
September 26, 2024 07:21 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035: Distribution by Application Area, Target Disease Indication and...
Xiaomi Auto's Electrification, Connectivity, Intelligence and Sharing Research Report 2024: Advantages and Shortcomings from the Development of their First Car
September 26, 2024 07:16 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Analysis on Xiaomi Auto's Electrification, Connectivity, Intelligence and Sharing, 2024" report has been added to ResearchAndMarkets.com's...
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
September 26, 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
AURG48 PRO - Nøkkelinformasjon ved innfrielse av deler av obligasjonslån
September 26, 2024 07:09 ET
|
Aurskog Sparebank
Utsteder: Aurskog SparebankISIN for obligasjonslånet: NO0010892284Dato for innfrielse: 30.09.2024Beløp som innfris: 41 millioner kronerUtestående beløp etter innfrielse: 309 millioner...
Goliath Upsizes Non-Brokered Private Placement From $15,725,500 To $16,120,500
September 26, 2024 07:08 ET
|
Goliath Resources Limited
TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to announce it has increased the previously...
Where Consumers Shop for Toys and Games in 2024: The Power of Pop Culture Influences Sales
September 26, 2024 07:07 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Where Consumers Shop for Toys and Games" report has been added to ResearchAndMarkets.com's offering. Despite the strong growth of e-commerce,...
UXLINK Now Listed on the Crypto.com
September 26, 2024 07:07 ET
|
UXLINK
SINGAPORE, Sept. 26, 2024 (GLOBE NEWSWIRE) -- UXLINK is excited to announce that $UXLINK is now officially listed on the Crypto.com App, one of the leading cryptocurrency...
Aurskog Sparebank: Utvidelse og nedkvittering av obligasjonslån
September 26, 2024 07:06 ET
|
Aurskog Sparebank
Aurskog Sparebank har i dag utvidet følgende obligasjonslån:AURG66 PRO ISIN NO0013257428. Utvidelse 50 millioner kroner. Ny beholdning er 300 millioner kroner, ramme er 500 millioner kroner. Banken...
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
September 26, 2024 07:02 ET
|
Pasithea
Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.